QSant, the first urine test for kidney transplant rejection, Featured at Biotech Showcase Digital 2022

NephroSant, a biotechnology company launched on University of California, San Francisco technology, and dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, announced that it will present a company overview at the upcoming Biotech Showcase conference.